Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
n-methyl-pyrrolidone
- Development stage
- Phase 1
- Lead developer
- Peter MacCallum Cancer Centre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
N-methyl-pyrrolidone (NMP) is a small molecule traditionally utilized as an industrial solvent and pharmaceutical excipient that is being repurposed as an active therapeutic agent for hematological malignancies. Research, primarily conducted at the Peter MacCallum Cancer Centre, has demonstrated that NMP possesses intrinsic anti-tumor and immunomodulatory activity by acting as a low-potency inhibitor of the bromodomain and extra-terminal (BET) family of proteins, including BRD4. This inhibition leads to the downregulation of key oncogenic drivers such as MYC and IRF4, which are critical for the survival and proliferation of multiple myeloma cells. NMP has been evaluated in Phase I clinical trials for patients with relapsed or refractory multiple myeloma who have exhausted standard treatment options, including lenalidomide and bortezomib.
- Brand names
- Pharmasolve
- Other names
- 1-methyl-2-pyrrolidoneN-methyl-2-pyrrolidoneN-methyl2-pyrrolidoneN-methyl 2-pyrrolidonePharmasolve
02
Targets
BRD4 (Bromodomain-containing protein 4)BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)
Beyond the preview
Go deeper on n-methyl-pyrrolidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on n-methyl-pyrrolidone.